Takeda Continues Its Diversification By Hiring French COO From GlaxoSmithKline
This article was originally published in PharmAsia News
Executive Summary
GSK vaccines executive Christophe Weber will join Takeda as chief operating officer next spring and could be installed as the Japanese pharma’s next CEO a year later. Ironically, Weber negotiated a joint venture with Takeda competitor Daiichi Sankyo in 2012 to challenge Takeda’s primacy in the Asian vaccines market.
You may also be interested in...
Bringing Urgency And Focus To Takeda: An Interview With Tachi Yamada
In a wide-ranging interview conducted at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business, of the key late-stage assets that will carry the company into the next decade, and of business development priorities in the post-Nycomed era.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.